epinephrine in the setting of cardiopulmonary arrest and also as a cardiotropic infusion for extremely low birth weight infants (ELBW) p750 g. 1 On the basis of poor survival rates and dismal neurodevelopmental outcome, they advise ''extreme caution'', related to the usage of catecholamine infusions in this population. While not disagreeing entirely with their conclusions, the use of ''extreme caution'' is misleading, as this implies possible adverse effects of the therapy, and perhaps emphasizing the ''appropriateness'' of these acute interventions would improve the clarity of their message. A recent review by Chamnanvanakij emphasizes the importance of both precipitating cause and duration of ''no flow'' state when assessing the outcome following cardiopulmonary resuscitation. 2 Epinephrine is universally accepted as the agent of choice for neonatal resuscitation but there is increasing evidence that epinephrine, particularly at higher doses, may actually cause harm, which may affect patient outcomes. Specifically, these include b-adrenergic receptor-mediated postresuscitation myocardial dysfunction and survival disadvantage, from animal and several large adult and pediatric randomized controlled trials. 3, 4 Current recommended doses of epinephrine for neonates are not evidence based, and are directly translated from animal and human adult studies. 5 The International Guidelines 2000 for Neonatal Resuscitation consider epinephrine to be a class one recommendation and recommend it be used when the heart rate remains <60 bpm after a minimum of 30 s of adequate ventilation and chest compressions. 6 Contrary to the conventional wisdom that if a little is good, more is better, evidence has been accumulating that high-dose epinephrine is not beneficial and may even impair organ function and survival after successful resuscitation. Many perinatal centers recommend doses of 0.5 mls for premature and 1.0 mls to full-term neonates, as estimation of weight may be inaccurate in an acute resuscitation setting. The potential implication is that extremely low birth weight infants receive much higher doses of epinephrine than are currently recommended (i.e. for a neonate who weighs 500 g (0.5 mls ¼ 50 mg ¼ 1000 mg/kg). Oftentimes neonates receive multiple doses of epinephrine over a short time period which further accentuates the problem.
Epinephrine is not the first line cardiotropic agent for circulatory compromise in most neonatal intensive care units. It is normally administered after failure of crystalloid therapy or sympathomimmetic agents (i.e. dopamine or dobutamine). In this study, all ELBW infants who received >1.0 mg/kg/min died, but 32% who received an infusion rate <1.0 mg/kg/min survived, suggesting a dichotomous effect. Data are not presented on the indication for treatment, postnatal age of commencement, duration of treatment or alternative cardiotropic agents, which may all influence survival and neurodevelopmental outcome. The authors conclude that the lack of survival advantage after higher doses of intravenous epinephrine may represent ''continuous cardiac resuscitation'', thus prolonging the dying process. It is scientifically plausible that higher doses of epinephrine, particularly when administered for prolonged periods, may have directly impaired myocardial performance, leading to a survival disadvantage. There is some evidence that the neonatal myocardium may indeed be particularly susceptible to cardiotoxicity, during prolonged epinephrine infusions. Caspi et al. 7 demonstrated significant impairments in myocardial compliance and microscopic evidence of sarcolemmal rupture, with increased cytoplasmic calcium deposition following prolonged epinephrine infusions in a neonatal porcine model compared to their adult counterparts. In addition, when newborn pigs were exposed to prolonged cardioplegic arrest, epinephrine administration resulted in a significant elevation in the left ventricular stiffness index (end-systolic elastance), when normal calcium perfusates were used but not in the presence of a low calcium perfusate. 8 This suggests that high intracellular calcium levels may be directly responsible for the myocardial necrosis. A recent study by Germankis 9 reported paradoxical hypotension in premature neonates following chronic catecholamine usage, which they speculated related to myocardial hypercontractility. In summary, although for different biological reasons to those the authors suggest, the place of epinephrine as a treatment option in neonatal intensive care needs careful evaluation.
In conclusion, the role of epinephrine as the resuscitation agent of choice for ELBW infants must be questioned. While the appropriateness of its administration in ''no hope'' situations, such as the extremely low birth weight infant, must be highlighted, evidence is also required on its clinical efficacy and potential adverse effects. The role of epinephrine as a cardiotropic agent in ELBW infants is unclear. The decision to provide inotropic support should be based on sound physiologic principles and take into account the structural immaturity of the preterm myocardium. The desired therapeutic agent should be chosen on its ability to correct the disturbance in cardiovascular physiology, whether it is a problem with myocardial contractility or cardiac loading conditions (i.e. preload or afterload). Specifically, the cumulative effects of incremental doses of epinephrine, administered to VLBW infants with hypotension, on these physiologic issues must be carefully investigated.
